Decreased Skeletal Muscle Mitochondrial DNA in Patients Treated with High-Dose Simvastatin
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Statins are generally well tolerated, but can cause myopathy1 and have been associated with mitochondrial abnormalities.2,3,4,5,6 The aim of this study was to determine whether muscle mitochondrial DNA (mtDNA) levels are altered during statin therapy. We retrospectively quantified mtDNA in 86 skeletal muscle biopsy specimens collected as part of a previously published7 clinical trial of high-dose simvastatin or atorvastatin versus placebo. Clinical Pharmacology & Therapeutics (2007) 81, 650–653. doi:10.1038/sj.clpt.6100124; published online 28 February 2007
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There was a positive overall correlation between changes in muscle ubiquinone and the change in mtDNA/nuclear DNA ratios (R = 0.63, P < 0.01), which was strongest in the simvastatin group (R = 0.76, P < 0.002).”
In the citing paper
“Decreased mitochondrial DNA (mtDNA): reduced levels were found in skeletal muscle biopsies taken from patients treated with simvastatin 80 mg/day for 8 weeks but not in those treated with atorvastatin 40 mg/day.83”
In the citing paper
“In hypercholesterolemic patients treated with simvastatin, the content of Q 10 in skeletal muscle was reduced, and this was paralleled by a reduction in mitochondrial content (estimated by citrate synthase [CS] activity and mitochondrial DNA content), but only when a lipophilic statin was used (simvastatin) (12,13).”
From Simvastatin Effects on Skeletal Muscle (2013) · cites this paper as [13]
In the citing paper
“Other studies with high simvastatin doses (80 mg/day) have reported decreased Q 10 protein content in muscle from simvastatin-treated patients (12,13), whereas studies using lower (20 mg/day) doses have been unable to demonstrate decreased muscle Q 10 protein content (14,15)”
From Simvastatin Effects on Skeletal Muscle (2013) · cites this paper as [13]
Citations
Cites
Thomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226 · cited 1×
“11 However, in a recent large French observational study (PRIMO)”
BackgroundJones, P., Kafonek, S., Laurora, I., & Hunninghake, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00965-x · Cited by 1,067
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway
Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A. M., & Koopmans, P. P. (1998) · AIDS · doi:10.1097/00002030-199814000-00004 · Cited by 847
Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy
Dalakas, M. C., Illa, I., Pezeshkpour, G. H., Laukaitis, J. P., Cohen, B., & Griffin, J. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004193221602 · Cited by 844 · cited 1×
“Clinical symptoms and mitochondrial alterations in these patients are very similar to those observed in SIM”
ResultChanges in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients
Côté, H. C. F., Brumme, Z. L., Craib, K. J. P., Alexander, C. S., Wynhoven, B., Ting, L., Wong, H., Harris, M., Harrigan, P. R., O'Shaughnessy, M. V., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012035 · Cited by 573 · cited 1×
“Drug-related mitochondrial toxicity in the setting of HIV antiretroviral therapy has been associated with changes in mtDNA level”
BackgroundSelf-citationStatin-associated myopathy with normal creatine kinase levels
Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., England, J. D. F., & and the Scripps Mercy Clinical Research Center* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00009 · Cited by 565
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial
PAIVA, H., THELEN, K., COSTER, R., SMET, J., PAEPE, B., MATTILA, K., LAAKSO, J., LEHTIMAKI, T., VONBERGMANN, K., & LUTJOHANN, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.03.006 · Cited by 308
Self-citationStatin-related adverse events: A meta-analysis
Silva, M. A., Swanson, A. C., Gandhi, P. J., & Tataronis, G. R. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.01.005 · Cited by 278 · cited 1×
“A recent meta-analysis of 18 randomized controlled trials at regular statin dose ( n e71,108) reported a higher rate of CK elevations, but a lower rate of myalgia in simvastatin than atorvastatin”
BackgroundAn Assessment of Statin Safety by Muscle Experts
Thompson, P. D., Clarkson, P. M., & Rosenson, R. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.013 · Cited by 259
Research works printed but not linked: 1
- Schalke B.B., 1992, N. Engl. J. Med, 327, 649
Cited by
Items 101–103 of 103
Vedarathinam, R. C., Rajkumar, Y., Prem, P. N., Vetriselvan, P., & Kurian, G. A. (2023) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.1144 · Cited by 1
Low Statin Doses Have No Effect on Plasma Concentrations of cfDNA or Muscle-Specific miRNA
Vrablík, M., Hubacek, J. A., Janoušková, K., Dlouhá, D., Laštůvka, J., & Adámková, V. (2025) · Folia Biologica · doi:10.14712/fb2025.0010
“In skeletal muscles from patients with SAMS (Stringer et al., 2013) and in muscle biopsies from patients taking high doses of statins (Schick et al., 2007), the content of mi - tochondrial DNA has been found decreased. miRNAs are stable, short RNA molecules (averaging 22 bp) that occur in the…”
Skeletal muscle toxicity and statins : role of mitochondrial adaptations
Singh, F. (2016) · theses.fr (ABES) · doi:10.70675/362675f3z0a19z46f5z977az009dcec8ed40
Metadata
- Authors
- Schick, B. A., Laaksonen, R., Frohlich, J. J., Päivä, H., Lehtimäki, T., Humphries, K. H., & Côté, H. C. F.
- Affiliations
- University of British Columbia (CA)
- Tampere University Hospital (FI)
- Corresponding author
- Côté, H C F
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-02-28
- Volume
- 81
- Issue
- 5
- Pages
- 650-653
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2019193819
- Cited by
- 103
- References
- 21
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 2 · 2021: 3 · 2020: 5 · 2019: 5 · 2018: 10 · 2017: 11 · 2016: 4 · 2015: 7 · 2014: 7 · 2013: 5 · 2012: 9
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Michael Smith Health Research BC
- University of British Columbia
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Keywords
- simvastatin, statin-induced myopathy, skeletal muscle, mitochondrial DNA, high-intensity statin therapy, atorvastatin, mitochondrial abnormalities, statin adverse effects
- MeSH terms
- Atorvastatin, Adult, Aged, DNA, Mitochondrial, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Longitudinal Studies, Male, Middle Aged, Mitochondria, Muscle, Pyrroles, Retrospective Studies, Ubiquinone, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.